Connect your AI

ADMA Biologics ADMA Interest income and other, net

Interest income and other, net at other companies

Adaptive BiotechnologiesADPT

——

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.02B-54.5%

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's interest income and other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's interest income and other, net?: ADMA Biologics (ADMA) reported interest income and other, net of $1.09M in Q1 2026.